Avanza Fonder AB Makes New $10.99 Million Investment in Danaher Co. (NYSE:DHR)

Avanza Fonder AB purchased a new stake in shares of Danaher Co. (NYSE:DHR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,876 shares of the conglomerate's stock, valued at approximately $10,990,000.

A number of other hedge funds also recently bought and sold shares of the company. Fort Pitt Capital Group LLC increased its position in Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate's stock worth $66,194,000 after acquiring an additional 7,421 shares during the period. Good Life Advisors LLC bought a new position in shares of Danaher during the 3rd quarter worth about $217,000. ORG Partners LLC raised its position in shares of Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate's stock valued at $636,000 after buying an additional 2,559 shares during the last quarter. Harvest Portfolios Group Inc. lifted its stake in shares of Danaher by 1.2% in the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate's stock valued at $56,233,000 after buying an additional 2,465 shares during the period. Finally, Stifel Financial Corp grew its position in Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate's stock worth $235,583,000 after buying an additional 11,216 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

NYSE DHR traded down $3.49 on Friday, hitting $238.41. 3,044,734 shares of the company were exchanged, compared to its average volume of 2,640,177. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market cap of $172.20 billion, a P/E ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The firm has a 50 day moving average of $234.85 and a two-hundred day moving average of $253.32.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the firm posted $2.02 earnings per share. Danaher's revenue for the quarter was up 3.1% compared to the same quarter last year. On average, equities analysts predict that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher's dividend payout ratio is presently 20.61%.

Analysts Set New Price Targets

DHR has been the subject of several recent research reports. Stifel Nicolaus upped their price target on Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a report on Wednesday, October 23rd. TD Cowen upped their target price on Danaher from $310.00 to $315.00 and gave the company a "buy" rating in a research note on Wednesday, October 23rd. Royal Bank of Canada decreased their price target on shares of Danaher from $333.00 to $311.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Bank of America upgraded shares of Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price objective for the company in a research note on Friday, December 13th. Finally, Stephens reiterated an "overweight" rating and set a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.